StockData
Natera, Inc. logo

Natera, Inc.

NTRANasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 10/30206% above fair value
$378.92−35.38 (-8.54%)

Close on Nov 2, 2026Market cap $54.62BP/E –Yield –

Natera BGI Genomics License Agreement by Year

BGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025] ($M)

Natera BGI Genomics License Agreement: $16.8M in FY2024, down 4.5% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2024
16.8
Period ended Dec 31, 2024
Change on a year earlier
-4.5%
17.6 in FY2023
History
4 years
Since FY2021
Sources
4
Documents cited below

Where the FY2024 figure comes from

Source: Form 10-K (2025-02-28) ↗

Reported in Form 10-K/10-Q Note — Collaborative & Licensing Arrangements (2019–2025Q3).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBGI Genomics License Agreement — Noncurrent Contract Liability ($M) [legacy through Q3 2025] ($M)Year on yearSource
FY2024Dec 31, 202416.8-4.5%Form 10-K (2025-02-28) ↗
FY2023Dec 31, 202317.6-12.0%Form 10-K (2024-02-29) ↗
FY2022Dec 31, 202220-2.0%Form 10-K (2023-03-01) ↗
FY2021Dec 31, 202120.4–Form 10-K (2022-02-25) ↗

Cite this data

StockData. (2026). Natera BGI Genomics License Agreement ($M), annual FY2021–FY2024 [Data set]. Compiled from Natera SEC filings and investor materials. https://stockdatahq.com/stocks/ntra/kpis/contract-liab-bgi-noncurrent

See every metric in the Natera KPI table. Data updated Nov 2, 2026.